What Advanced Biological Laboratories (ABL) does

Advanced Biological Laboratories (ABL) S.A. is a Luxembourg-headquartered European biotechnology and MedTech group founded in 2000 that develops and commercializes molecular diagnostics products for infectious disease and liver function assessment. The company operates primarily through its wholly-owned subsidiary ABL Diagnostics SA, which is listed on Euronext Paris (compartment C, ISIN FR001400AHX6), and through Humedics GmbH, a Berlin-based MedTech subsidiary acquired in December 2022 that owns the CE-marked LiMAx® breath-based liver function test.

ABL's product portfolio is built around two core molecular platforms: DeepChek® sequencing-based genotyping assays and software, and UltraGene® real-time PCR assays and instruments, together covering HIV, viral hepatitis B and C, CMV, HSV, HPV, SARS-CoV-2, tuberculosis, and 16S rRNA microbiome applications. The DeepChek® and ViroScore® software products perform downstream Sanger and NGS data analysis, genotyping, mutation detection, and clinical interpretation including drug resistance profiling, underpinned by a proprietary database described as the world's most complete collection of patented HBV drug resistance mutations. Beyond molecular diagnostics, ABL offers the Nadis® CE-marked Electronic Medical Record system deployed in more than 200 French hospitals for HIV and viral hepatitis patient management, the LiMAx® breath test for quantitative liver function measurement, and MediaChek® specimen collection kits.

ABL's business model combines one-time assay kit sales (UltraGene®, DeepChek® assays) with recurring revenue from software licenses and subscriptions (DeepChek® Software, ViroScore®) and SaaS-like EMR contracts (Nadis®). The company commercializes globally through its own sales team and a network of exclusive distributors across Africa, Asia Pacific, Europe, the Middle East, North America, and South America, with its technology active in more than 75 countries via the Humedics/CytoSorbents collaboration. ABL is founder-led by Dr. Chalom Sayada and is pursuing a proposed reverse merger with ProPhase Labs (NASDAQ:PRPH) that would give ABL shareholders approximately 76% of a combined Nasdaq-listed entity at up to $30 million enterprise value.

Name

Advanced Biological Laboratories (ABL)

Legal name

Advanced Biological Laboratories (ABL) S.A.

Website

https://ablsa.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Advanced Biological Laboratories (ABL) is a Luxembourg-based European biotech and MedTech group developing molecular diagnostics assays (DeepChek®, UltraGene®), bioinformatics software, and the LiMAx® breath-based liver function test, serving clinical pathology labs, reference labs, and hospitals across more than 75 countries.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Software

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Molecular diagnostics software
• Clinical genomics analysis
• PCR assay kits
• Infectious disease genotyping
• Liver function diagnostics

Headquarters

HQ city

Luxembourg

HQ country

Luxembourg

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Molecular Biology Products: Sale of innovative and proprietary molecular biology assays (UltraGene® and DeepChek® product lines) generating recurring revenues with primary focus on HIV, SARS-CoV-2, Tuberculosis, and viral hepatitis B and C applications.
2. Software Licenses and Subscriptions: Commercialization of DeepChek® and ViroScore® software solutions for sequencing data analysis, with regular updates, quarterly upgrades, and cloud or local server deployment options.
3. Clinical Specimen Collection Kits: Manufacturing and marketing of MediaChek® kits for clinical specimen collection.
4. Digital Health Solutions: Sale of Nadis®, a CE-marked Electronic Medical Record (EMR) system used in France in more than 200 hospitals managing patients infected by HIV or Viral Hepatitis.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Advanced Biological Laboratories (ABL) develops and commercializes molecular biology assays and downstream bioinformatics software for infectious disease diagnostics. Its DeepChek® and ViroScore® software platforms analyze Sanger and Next Generation Sequencing data for genotyping, subtyping, amino-acid mutation detection, and drug resistance interpretation across HIV, HBV, HCV, CMV, HSV, HPV, tuberculosis, SARS-CoV-2, and microbiome targets. UltraGene® real-time PCR assays provide CE-IVD marked viral load detection and variant screening, while the LiMAx® breath test (acquired via Humedics) measures enzymatic liver function and the Nadis® EMR system manages HIV and viral hepatitis patient records in over 200 French hospitals.

Product overview

Advanced Biological Laboratories (ABL) offers a comprehensive molecular diagnostics portfolio centered on two core platforms: DeepChek® and ViroScore® software for downstream sequencing data analysis, and UltraGene® molecular assays for PCR-based detection and quantification. DeepChek® software handles Sanger and Next Generation Sequencing data for genomic analysis including genotyping, subtyping, and drug resistance interpretation across HIV, HCV, HBV, CMV, HSV, HPV, TB, and SARS-CoV-2. The companion UltraGene® assay line includes real-time PCR tests for viral load detection and variant screening, with products covering respiratory viruses (SARS-CoV-2, Influenza, RSV), viral hepatitis (HIV, HCV, HBV), and bacterial targets (TB, 16S rRNA). ABL also offers the LiMAx® breath analysis diagnostic (acquired via Humedics) for liver function measurement, the Nadis® EMR system for HIV/viral hepatitis patient management, and the MediaChek® specimen collection kits. The portfolio includes both CE-IVD marked diagnostic products and Research Use Only (RUO) assays, distributed globally through ABL Diagnostics SA (Euronext Paris listed) and a network of exclusive distributors.

Differentiator

Problem solved

Functional benefit

Brands

• DeepChek: Sequencing-based genotyping assays and downstream analysis software for microbiology and virology applications including HIV, HBV, HCV, CMV, HSV, HPV, Tuberculosis, Coronavirus, and microbiome analysis
• UltraGene
• ViroScore
• SeqHepB
• Nadis
• MediaChek
• LiMAx

Products and services

• DeepChek® Software
• ViroScore® Software
• SeqHepB
• BacterioChek®-TB Software
• UltraGene® qPCR Instrument
• MediaChek®
• Nadis®
• LiMAx®
• DeepChek® HIV Assay INT Genotyping and Drug Resistance
• DeepChek® HIV Assay Protease / Reverse Transcriptase Genotyping and Drug Resistance
• DeepChek® HCV 5'UTR Genotyping Assay
• DeepChek® HCV NS3 Drug Resistance Assay
• DeepChek® HCV NS5A Drug Resistance Assay
• DeepChek® HCV NS5B Drug Resistance V4 Assay
• DeepChek® HBV RT Genotyping and Drug Resistance Assay
• DeepChek® CMV UL54/UL97 Assay
• DeepChek® HSV TK/POL Assay
• DeepChek® Whole Genome SARS-CoV-2 Genotyping Assay
• DeepChek® 16S rRNA Bacterial Identification Assay
• DeepChek® 13-Plex KB Drug Susceptibility Testing Assay
• UltraGene® Assay SARS-CoV-2 VOC Screening and Determination
• UltraQuant® Assay SARS-CoV-2 Quantification
• UltraGene® Assay Combo 4 Screening
• TherapyEdge®

Quantifiable outcome

• Eliminates 51 manual connection steps in poxvirus downstream processing
• +1 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• Ginkgo BioworkscoreStrategic or Co-development Partner · 4 November 2025Advanced BioScience Laboratories (ABL subsidiary) is part of Ginkgo Bioworks' multi-organization team for BARDA's BioMaP-Consortium contract (up to $22.2M) to develop domestic biomanufacturing of monoclonal antibodies targeting filoviruses. ABL contributes to scale production of 1C3 and 1C11 mAbs cocktail discovered by Emory University.
• Institut PasteurcoreTechnology or Integration · 22 April 2025ABL signed licensing agreement with Institut Pasteur for HPV RNA-Seq Technology. HPV Transcriptome technology serves as a biomarker for detection, genotyping, and monitoring of HPV-associated cervical high-grade cytology.
• Siemens HealthineerscoreTechnology or Integration · 3 February 2025ABL signed know-how license and transfer agreement for Fast Track Diagnostics PCR portfolio from Siemens Healthineers. ABL and affiliates plan to start production and commercialization of new UltraGene products based on PCR tests previously supplied by Fast Track Diagnostics.
• CytoSorbents CorporationcoreStrategic or Co-development Partner · 11 July 2023Humedics GmbH (ABL subsidiary) and CytoSorbents announced theranostic collaboration in liver disease. Joint product promotion and comarketing program to increase market awareness, adoption, and sales of LiMAx® diagnostic and CytoSorb® therapy technologies across Europe (Germany, UK, France, Austria, Switzerland, Belgium, Netherlands, Luxembourg, Finland, Norway, Sweden, and Poland).

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• QIAGEN: Global molecular diagnostics and sample-preparation leader with PCR/qPCR and NGS-based assay menus (e.g., QIAstat-Dx) covering infectious diseases including HIV, HCV, HBV and TB — directly comparable to ABL's UltraGene®/DeepChek® clinical microbiology offerings, but at vastly greater scale.
• Hologic: Diversified diagnostics company with FDA-cleared molecular assays (e.g., Panther system, Aptima HIV/HCV viral load assays) targeted at clinical laboratories — competes with ABL's CE-IVD HIV/HCV/HBV assay portfolio from a global installed-base advantage.
• Cepheid (Danaher): Developer of the GeneXpert molecular diagnostics platform with broad FDA-cleared infectious-disease menu (HIV, HCV, MTB, SARS-CoV-2) — competes head-to-head with ABL's assay offerings in reference and clinical labs and benefits from a much larger global installed base.
• bioMérieux: French in vitro diagnostics leader with strong microbiology and molecular infectious-disease franchises (BioBall, BIOFIRE, ARGENE) — directly comparable to ABL on TB/HIV/HCV molecular diagnostics and shares ABL Diagnostics' Euronext Paris corporate ecosystem.
• Roche Diagnostics: World's largest IVD player with cobas® and cobas® 6800/8800 molecular systems covering HIV, HCV, HBV, CMV viral-load testing and broader infectious-disease menu — sets the standard ABL's CE-IVD assays must compete against globally.
• Abbott Molecular: Division of Abbott with m2000 and Alinity m molecular platforms and FDA-cleared assays (HIV, HCV, HBV, CT/NG, SARS-CoV-2) — comparable assay menu across ABL's viral hepatitis/HIV/respiratory focus at much larger U.S. clinical scale.

Direct peers

• Seegene: South Korea-based molecular diagnostics specialist known for multiplex real-time PCR syndromic panels and proprietary assay design — closely mirrors ABL's UltraGene® quantitative PCR and Combo 4 respiratory panel strategy for infectious disease testing in clinical labs.
• ELITechGroup: European IVD company focused on molecular diagnostics (PCR-based) and clinical chemistry with similar mid-market positioning to ABL Diagnostics — overlapping customer base of academic and reference labs across EMEA.
• Vela Diagnostics: Singapore-headquartered molecular diagnostics company with integrated PCR + NGS workflows for viral genotyping and resistance testing (HIV, HCV, HBV, influenza) and a similar reagent-plus-software value proposition to ABL's DeepChek®.

Others

• Humedics: Now an ABL subsidiary itself, Humedics originated the LiMAx® breath test — comparable as an enabling/adjacent business but illustrates the de-facto reference point for liver-function diagnostics competitors such as Echosens (FibroScan) and LiverMultiScan providers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ablsa2
• LinkedInlinkedin.com/company/abl-sa

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced Biological Laboratories (ABL)